Denali Therapeutics Inc
NASDAQ:DNLI

Watchlist Manager
Denali Therapeutics Inc Logo
Denali Therapeutics Inc
NASDAQ:DNLI
Watchlist
Price: 24.69 USD 1.94% Market Closed
Market Cap: 3.6B USD
Have any thoughts about
Denali Therapeutics Inc?
Write Note

Intrinsic Value

DNLI's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one DNLI stock under the Base Case scenario is 16.81 USD. Compared to the current market price of 24.69 USD, Denali Therapeutics Inc is Overvalued by 32%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

DNLI Intrinsic Value
16.81 USD
Overvaluation 32%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Denali Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for DNLI cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about DNLI?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Denali Therapeutics Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Denali Therapeutics Inc

Provide an overview of the primary business activities
of Denali Therapeutics Inc.

What unique competitive advantages
does Denali Therapeutics Inc hold over its rivals?

What risks and challenges
does Denali Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Denali Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Denali Therapeutics Inc.

Provide P/S
for Denali Therapeutics Inc.

Provide P/E
for Denali Therapeutics Inc.

Provide P/OCF
for Denali Therapeutics Inc.

Provide P/FCFE
for Denali Therapeutics Inc.

Provide P/B
for Denali Therapeutics Inc.

Provide EV/S
for Denali Therapeutics Inc.

Provide EV/GP
for Denali Therapeutics Inc.

Provide EV/EBITDA
for Denali Therapeutics Inc.

Provide EV/EBIT
for Denali Therapeutics Inc.

Provide EV/OCF
for Denali Therapeutics Inc.

Provide EV/FCFF
for Denali Therapeutics Inc.

Provide EV/IC
for Denali Therapeutics Inc.

Show me price targets
for Denali Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Denali Therapeutics Inc?

How accurate were the past Revenue estimates
for Denali Therapeutics Inc?

What are the Net Income projections
for Denali Therapeutics Inc?

How accurate were the past Net Income estimates
for Denali Therapeutics Inc?

What are the EPS projections
for Denali Therapeutics Inc?

How accurate were the past EPS estimates
for Denali Therapeutics Inc?

What are the EBIT projections
for Denali Therapeutics Inc?

How accurate were the past EBIT estimates
for Denali Therapeutics Inc?

Compare the revenue forecasts
for Denali Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Denali Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Denali Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Denali Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Denali Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Denali Therapeutics Inc with its peers.

Analyze the financial leverage
of Denali Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Denali Therapeutics Inc.

Provide ROE
for Denali Therapeutics Inc.

Provide ROA
for Denali Therapeutics Inc.

Provide ROIC
for Denali Therapeutics Inc.

Provide ROCE
for Denali Therapeutics Inc.

Provide Gross Margin
for Denali Therapeutics Inc.

Provide Operating Margin
for Denali Therapeutics Inc.

Provide Net Margin
for Denali Therapeutics Inc.

Provide FCF Margin
for Denali Therapeutics Inc.

Show all solvency ratios
for Denali Therapeutics Inc.

Provide D/E Ratio
for Denali Therapeutics Inc.

Provide D/A Ratio
for Denali Therapeutics Inc.

Provide Interest Coverage Ratio
for Denali Therapeutics Inc.

Provide Altman Z-Score Ratio
for Denali Therapeutics Inc.

Provide Quick Ratio
for Denali Therapeutics Inc.

Provide Current Ratio
for Denali Therapeutics Inc.

Provide Cash Ratio
for Denali Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Denali Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Denali Therapeutics Inc?

What is the current Free Cash Flow
of Denali Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Denali Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Denali Therapeutics Inc

Current Assets 868.8m
Cash & Short-Term Investments 836.6m
Other Current Assets 32.3m
Non-Current Assets 585.2m
Long-Term Investments 445.5m
PP&E 113.2m
Other Non-Current Assets 26.5m
Current Liabilities 87.1m
Accounts Payable 9.6m
Accrued Liabilities 61.2m
Other Current Liabilities 16.3m
Non-Current Liabilities 48.4m
Long-Term Debt 5.6m
Other Non-Current Liabilities 42.8m
Efficiency

Earnings Waterfall
Denali Therapeutics Inc

Revenue
0 USD
Operating Expenses
-504.6m USD
Operating Income
-504.6m USD
Other Expenses
77.1m USD
Net Income
-427.5m USD

Free Cash Flow Analysis
Denali Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

DNLI Profitability Score
Profitability Due Diligence

Denali Therapeutics Inc's profitability score is 13/100. The higher the profitability score, the more profitable the company is.

13/100
Profitability
Score

Denali Therapeutics Inc's profitability score is 13/100. The higher the profitability score, the more profitable the company is.

DNLI Solvency Score
Solvency Due Diligence

Denali Therapeutics Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
87/100
Solvency
Score

Denali Therapeutics Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

DNLI Price Targets Summary
Denali Therapeutics Inc

Wall Street analysts forecast DNLI stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DNLI is 42.53 USD with a low forecast of 28.28 USD and a high forecast of 94.5 USD.

Lowest
Price Target
28.28 USD
15% Upside
Average
Price Target
42.53 USD
72% Upside
Highest
Price Target
94.5 USD
283% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for DNLI?

Click here to dive deeper.

Dividends

Denali Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for DNLI is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

DNLI Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Denali Therapeutics Inc Logo
Denali Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

3.6B USD

Dividend Yield

0%

Description

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. The company is headquartered in South San Francisco, California and currently employs 380 full-time employees. The company went IPO on 2017-12-08. The firm is focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The firm clinical programs include leucine-rich repeat kinase 2 (LRRK2) inhibitor program, eukaryotic initiation factor 2 B (EIF2B) activator program, enzyme transport vehicle: iduronate 2-sulfatase (ETV:IDS) program, receptor interacting serine/threonine protein kinase 1 (RIPK1) inhibitor program and second non-CNS penetrant RIPK1 inhibitor. The firm engineers its product candidates to cross the blood-brain barrier (BBB), and act directly in the brain. Its pipeline includes approximately 15 programs that are based on its TV technology, including the lead program ETV:IDS (DNL310). Its product pipeline includes DNL151, DNL593 (PTV:PGRN), DNL126 (ETV:SGSH), DNL919 (ATV:TREM2), DNL788, DNL343, DNL758 and others.

Contact

CALIFORNIA
South San Francisco
161 Oyster Point Blvd
+16508668548.0
www.denalitherapeutics.com

IPO

2017-12-08

Employees

380

Officers

Co-Founder, President, CEO & Director
Dr. Ryan J. Watts Ph.D.
Co-Founder, CFO, COO & Secretary
Dr. Alexander O. Schuth M.D.
Co-Founder & Independent Director
Dr. Marc Tessier-Lavigne Ph.D.
Chief Medical Officer & Head of Development
Dr. Carole Ho M.D.
Senior Vice President of Corporate Finance
Mr. Tyler M. Nielsen
Chief Technical and Manufacturing Officer
Dr. Dana Andersen
Show More
Chief Scientific Officer
Mr. Joe Lewcock Ph.D.
Vice President of Investor Relations
Dr. Laura Hansen
General Counsel
Mr. Chris Walsh
Vice President of Corporate Development
Mr. Mark Rowen
Show Less

See Also

Discover More
What is the Intrinsic Value of one DNLI stock?

The intrinsic value of one DNLI stock under the Base Case scenario is 16.81 USD.

Is DNLI stock undervalued or overvalued?

Compared to the current market price of 24.69 USD, Denali Therapeutics Inc is Overvalued by 32%.

Back to Top